Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction

Mohammad, Moman A; Koul, Sasha; Egerstedt, Anna; Smith, Josh; Noč, Marko; Lang, Irene; Hölzer, Michael; Clemmensen, Peter; Gidlöf, Olof; Metzler, Bernhard; Engstrøm, Thomas; Erlinge, David

doi:10.1038/s41598-020-75399-6

Cited by 10 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The multiplex PEA is a relatively new high-throughput technique increasingly used in human biomarker research. Many promising prognostic biomarkers have been detected using the PEA technique [ 15 , 16 , 26 , 27 ]. However, the PEA data are expressed in relative NPX-unit whereas conventional immunoassays present absolute concentrations.…”

Section: Discussionmentioning

confidence: 99%

Are the results from a multiplex proteomic assay and a conventional immunoassay for NT-proBNP and GDF-15 comparable?

et al. 2023

View full text Add to dashboard Cite

Background We aimed to compare absolute plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) and growth differentiation factor 15 (GDF-15) obtained by a conventional immunoassay with the corresponding relative concentrations from a proximity extension assay (PEA) and compare the prognostic impact of the protein levels obtained from these assays. Methods We evaluated 437 patients with peripheral arterial disease (PAD) and a population-based cohort of 643 individuals without PAD. Correlations were calculated using Spearman’s rank correlation coefficients (rho). The discriminatory accuracy of the protein levels to predict future cardiovascular events was analyzed with Cox regression and presented as time-dependent areas under the receiver-operator-characteristic curves (tdAUCs). Results For NT-proBNP, the two assays correlated with rho 0.93 and 0.93 in the respective cohort. The PEA values leveled off at higher values in both cohorts. The corresponding correlations for GDF-15 were 0.91 and 0.89. At 5 years follow-up, the tdAUCs in the patient cohort were similar for NT-proBNP and GDF-15 regardless of assay used (0.65–0.66). The corresponding tdAUCs in the population-based cohort were between 0.72 and 0.77. Conclusion Except for the highest levels of NT-proBNP, we suggest that PEA data for NT-proBNP and GDF-15 reliably reflects absolute plasma levels and contains similar prognostic information.

show abstract

Section: Discussionmentioning

confidence: 99%

Are the results from a multiplex proteomic assay and a conventional immunoassay for NT-proBNP and GDF-15 comparable?

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Interestingly, IL-6 seems to be a driver for proinflammatory responses related to the impairment of microcirculation [ 15 ], affecting the recovery of ischemic tissue post myocardial infarction. Recently, IL-6 was identified as one of the strongest biomarker for infarcted size and LVEF among 131 inflammatory and cardiac biomarkers in subjects after STEMI [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

Role of B lymphocytes in the infarcted mass in patients with acute myocardial infarction

et al. 2021

View full text Add to dashboard Cite

Despite early reperfusion, patients with ST segment elevation myocardial infarction (STEMI) may present large myocardial necrosis and significant impairment of ventricular function. The present study aimed to evaluate the role of subtypes of B lymphocytes and related cytokines in the infarcted mass and left ventricular ejection fraction obtained by cardiac magnetic resonance imaging performed after 30 days of STEMI. This prospective study included 120 subjects with STEMI submitted to pharmacoinvasive strategy. Blood samples were collected in subjects in the first (D1) and 30th (D30) days post STEMI. The amount of CD11b+ B1 lymphocytes (cells/ml) at D1 were related to the infarcted mass (rho = 0.43; P=0.033), measured by cardiac MRI at D30. These B1 cells were associated with CD4+ T lymphocytes at D1 and D30, while B2 classic lymphocytes at day 30 were related to left ventricular ejection fraction (LVEF). Higher titers of circulating IL-4 and IL-10 were observed at D30 versus D1 (P=0.013 and P<0.001, respectively). Titers of IL-6 at D1 were associated with infarcted mass (rho = 0.41, P<0.001) and inversely related to LVEF (rho = −0.38, P<0.001). After multiple linear regression analysis, high-sensitivity troponin T and IL-6 collected at day 1 were independent predictors of infarcted mass and, at day 30, only HDL-C. Regarding LVEF, high-sensitivity troponin T and high-sensitivity C-reactive protein were independent predictors at day 1, and B2 classic lymphocytes, at day 30. In subjects with STEMI, despite early reperfusion, the amount of infarcted mass and ventricular performance were related to inflammatory responses triggered by circulating B lymphocytes.

show abstract

“…These biomarkers include apolipoprotein A1, immunoglobulin A, interleukin-17E, tissue inhibitor of metalloproteinases-1, urokinase-type plasminogen activator, midkine, proprotein convertase subtilisin/kexin type 6, among others ( 170 , 173 , 174 ). Furthermore, proteomic studies can provide useful information in assessing left ventricular ejection fraction (LVEF) and infarct size after MI ( 175 ).…”

Section: Single-omics Approachesmentioning

confidence: 99%

From multi-omics approaches to personalized medicine in myocardial infarction

Zhan,

Tang,

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Myocardial infarction (MI) is a prevalent cardiovascular disease characterized by myocardial necrosis resulting from coronary artery ischemia and hypoxia, which can lead to severe complications such as arrhythmia, cardiac rupture, heart failure, and sudden death. Despite being a research hotspot, the etiological mechanism of MI remains unclear. The emergence and widespread use of omics technologies, including genomics, transcriptomics, proteomics, metabolomics, and other omics, have provided new opportunities for exploring the molecular mechanism of MI and identifying a large number of disease biomarkers. However, a single-omics approach has limitations in understanding the complex biological pathways of diseases. The multi-omics approach can reveal the interaction network among molecules at various levels and overcome the limitations of the single-omics approaches. This review focuses on the omics studies of MI, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, and other omics. The exploration extended into the domain of multi-omics integrative analysis, accompanied by a compilation of diverse online resources, databases, and tools conducive to these investigations. Additionally, we discussed the role and prospects of multi-omics approaches in personalized medicine, highlighting the potential for improving diagnosis, treatment, and prognosis of MI.

show abstract

Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction after ST-elevation myocardial infarction

Cited by 10 publications

References 39 publications

Are the results from a multiplex proteomic assay and a conventional immunoassay for NT-proBNP and GDF-15 comparable?

Are the results from a multiplex proteomic assay and a conventional immunoassay for NT-proBNP and GDF-15 comparable?

Role of B lymphocytes in the infarcted mass in patients with acute myocardial infarction

From multi-omics approaches to personalized medicine in myocardial infarction

Contact Info

Product

Resources

About